Hyungwon Kang / REUTERS

S.Africa's Adcock sees lower FY profit, shares fall

Adcock Ingram, South Africa's second-biggest drug maker, said on Monday it expects full-year profit to fall by as much as 22 percent, stung by a one-off charge related to a black empowerment deal.

Xoma Could Initiate Pivotal Behcet’s Trial by Year-End 2011: Analyst

RBC Capital Markets said Xoma Ltd. (NASDAQ: XOMA) continues to make steady albeit measured progress toward initiating a pivotal trial in Behcet’s disease, which could begin by year-end 2011, pending regulatory feedback.

Week Ahead in Life Sciences

Wedbush Securities said that among the companies it covered in Life Sciences this week Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) are reporting earnings.

Cash Runway Expected for Xoma Through Start of Phase 3 Behcet's Uveitis Study: Analyst

Wedbush Securities expects cash runway for XOMA Ltd. (NASDAQ: XOMA) through start of phase 3 Behcet’s Uveitis study by year-end 2011.

Seattle Genetics drug gets priority FDA review

The U.S. Food and Drug Administration will review a Seattle Genetics Inc experimental drug for two types of lymphoma on a priority basis, the company said on Monday.

Dubai

A security guard walks past a shipment of copper in a file photo.

Dubai firm plans $500 mln copper smelter in Tanzania

10:13 AM ET

Dubai-based City Energy & Infrastructure LLC plans to build a copper smelter and sugar plant in Tanzania over the next three years at a...

Nigeria

Nigeria's FCMB 9-month pre-tax profit up 62 pct

10:21 AM ET

Nigeria's First City Monument Bank said on Monday its pre-tax profit rose by 62 percent to 9.88 billion naira for the nine months to September, from 6.